We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A faster magnetic resonance imaging (MRI) data-acquisition technique will cut the time many patients spend in a cramped magnetic resonance scanner, yet deliver more precise 3-D images of their bodies.
Darla Russell and Leah Coppersmith had chronic lower back problems when their doctors suggested an artificial spinal disc implant to reduce their pain and restore their mobility.
A Cambridge company developing technology that could save lives in intensive care units has signed a breakthrough commercialisation deal that could spell an imminent IPO.
InfraScan, a medical device firm specializing in brain injury diagnostic products, announced that more than 15 patients have been enrolled in its clinical trial for hematoma detection.
A test that measures the generation of a certain protein involved with blood clotting can help determine whether patients who have experienced a venous blood clot are at low risk of developing another blood clot, and thus avoiding anticoagulant treatment and its possible side effects, according to a study in the July 26 issue of JAMA.
Stratagene Corp. said the jury determined that Invitrogen Corp.'s 4,981,797 patent is valid and that Stratagene infringed that patent by making and selling its competent E. coli cell products.
A study in the Journal of Invasive Cardiology published July 26 found an increased risk of serious adverse events following cardiac catheterization with certain devices used in hemostasis, a process to stop bleeding.
A guidance posted July 26 on the FDA website describes how in vitro diagnostic devices to measure fecal calprotectin in human stool specimens can comply with the special controls requirement for Class II devices.
The FDA sent personal hemodialysis (PHD) system maker Aksys a June 8 warning letter saying that its devices were adulterated and misbranded because the company changed its recommendation for how long patients should use the system without requesting premarket approval.
Venture capital funding, the lifeblood of the high-tech and life-sciences industries, was up slightly nationwide during the second quarter but rose 8 percent for New England firms.